2026 Global: Insulin Delivery Devices Market-Competitive Review (2032) report
Description
The 2026 Global: Insulin Delivery Devices Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Novo Nordisk A/S — Bagsværd, Denmark; Novo Nordisk remains the leading force in insulin-delivery devices, supported by the extensive NovoPen family and compatible needle technologies that underwrite modern pen-based therapy. Eli Lilly and Company — Indianapolis, United States; Lilly has built a durable portfolio of insulin-delivery options, combining reliable disposable pens with precision dosing features and global reach essential for clinicians and patients across diverse healthcare landscapes. Sanofi — Paris, France; Sanofi maintains a broad insulin-delivery footprint, including syringe-based and pen-based devices designed for ease of use, safety, and adherence, with emphasis on compatibility with its insulins across markets. Medtronic plc — Dublin, Ireland; Medtronic anchors the pump segment of the market, offering infusion pumps, tubing and infusion sets, and integration with continuous glucose monitoring systems to deliver comprehensive insulin therapy for many patients. Together they shape device ergonomics, data interoperability, and market access across global regions for better outcomes.
Tandem Diabetes Care — San Diego, United States; Tandem is a leading insulin pump manufacturer known for its touchscreen interfaces, compact form factor, and the t:slim X2 pump with integrated CGM compatibility. The company emphasizes patient-centric design and software updates to optimize dosing and safety in real-time. Insulet Corporation — Acton, United States; Insulet’s Omnipod insulin delivery system delivers tubeless, waterproof, patch-like pumps and automated dosing workflows; its device design supports pediatric and adult therapy, with expansion into connected CGM ecosystems through partnerships and data sharing. Ypsomed AG — Burgdorf, Switzerland; Ypsomed specializes in insulin pen technology and device platforms, including the My Life and YpsoPen lines, and supports customizable injection devices that address patient preference, portability, and dosing accuracy. These firms collectively advance the move toward pump-pen hybrids and interoperable systems, accelerating adoption in both developed and emerging markets. Their collaborations with manufacturers and payers shape access dynamics globally.
Terumo Corporation — Tokyo, Japan; Terumo contributes to insulin-delivery ecosystems with infusion sets, injection devices, and safety technologies that support pump therapy and pen-based systems, emphasizing reliability, sterilization, and supply resilience. Nipro Corporation — Osaka, Japan; Nipro produces syringes, needles, and disposable injection devices widely used with insulin regimens and also supplies sterile packaging and other consumables essential to dose accuracy. Becton, Dickinson and Company (BD) — Franklin Lakes, United States; BD offers a broad portfolio of safety-enhanced syringes, infusion components, and insulin-delivery accessories, supported by global manufacturing and regulatory compliance. These capabilities extend to training and customer support, enabling consistent device handling, dosing accuracy, and maintenance across settings. Their combined presence underpins access to insulin therapy, particularly in regions with expanding diabetes prevalence. Continued investment in device safety, interoperability, and patient education remains central to expanding durable adoption worldwide. Regulators favor standardized interfaces, accelerating market access for newer platforms.
Novo Nordisk A/S — Bagsværd, Denmark; Novo Nordisk remains the leading force in insulin-delivery devices, supported by the extensive NovoPen family and compatible needle technologies that underwrite modern pen-based therapy. Eli Lilly and Company — Indianapolis, United States; Lilly has built a durable portfolio of insulin-delivery options, combining reliable disposable pens with precision dosing features and global reach essential for clinicians and patients across diverse healthcare landscapes. Sanofi — Paris, France; Sanofi maintains a broad insulin-delivery footprint, including syringe-based and pen-based devices designed for ease of use, safety, and adherence, with emphasis on compatibility with its insulins across markets. Medtronic plc — Dublin, Ireland; Medtronic anchors the pump segment of the market, offering infusion pumps, tubing and infusion sets, and integration with continuous glucose monitoring systems to deliver comprehensive insulin therapy for many patients. Together they shape device ergonomics, data interoperability, and market access across global regions for better outcomes.
Tandem Diabetes Care — San Diego, United States; Tandem is a leading insulin pump manufacturer known for its touchscreen interfaces, compact form factor, and the t:slim X2 pump with integrated CGM compatibility. The company emphasizes patient-centric design and software updates to optimize dosing and safety in real-time. Insulet Corporation — Acton, United States; Insulet’s Omnipod insulin delivery system delivers tubeless, waterproof, patch-like pumps and automated dosing workflows; its device design supports pediatric and adult therapy, with expansion into connected CGM ecosystems through partnerships and data sharing. Ypsomed AG — Burgdorf, Switzerland; Ypsomed specializes in insulin pen technology and device platforms, including the My Life and YpsoPen lines, and supports customizable injection devices that address patient preference, portability, and dosing accuracy. These firms collectively advance the move toward pump-pen hybrids and interoperable systems, accelerating adoption in both developed and emerging markets. Their collaborations with manufacturers and payers shape access dynamics globally.
Terumo Corporation — Tokyo, Japan; Terumo contributes to insulin-delivery ecosystems with infusion sets, injection devices, and safety technologies that support pump therapy and pen-based systems, emphasizing reliability, sterilization, and supply resilience. Nipro Corporation — Osaka, Japan; Nipro produces syringes, needles, and disposable injection devices widely used with insulin regimens and also supplies sterile packaging and other consumables essential to dose accuracy. Becton, Dickinson and Company (BD) — Franklin Lakes, United States; BD offers a broad portfolio of safety-enhanced syringes, infusion components, and insulin-delivery accessories, supported by global manufacturing and regulatory compliance. These capabilities extend to training and customer support, enabling consistent device handling, dosing accuracy, and maintenance across settings. Their combined presence underpins access to insulin therapy, particularly in regions with expanding diabetes prevalence. Continued investment in device safety, interoperability, and patient education remains central to expanding durable adoption worldwide. Regulators favor standardized interfaces, accelerating market access for newer platforms.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
